Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as a intravenous formulation for intravenous use. It treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, osteosarcoma, and gestational trophoblastic disease in appropriate patients.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Methotrexate acts on rapidly proliferating cells and modulates immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant lymphoblast proliferation. - Osteosarcoma: impedes tumor growth and metastasis. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methofill may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting. - Mucositis and oral ulceration. - Fatigue and weakness. - Alopecia (hair loss). - Elevated liver enzymes. - Mild rash.

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia. - Pulmonary toxicity (interstitial pneumonitis). - Severe hepatotoxicity or fibrosis. - Acute renal failure. - Life‑threatening infections. - Anaphylactic or severe hypersensitivity reactions.

Methofill requires careful monitoring and specific safety measures before and during therapy. - Pregnancy testing: avoid use in pregnancy (Category X). - Baseline labs: monitor liver function, renal function, and complete blood counts. - Infection risk: screen for active infections and vaccinate appropriately before initiation. - Drug interactions: avoid concurrent high‑dose NSAIDs, penicillins, and sulfonamides that increase toxicity. - Patient counseling: advise on folic acid supplementation and signs of mucosal ulceration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with several medicines, requiring avoidance or close monitoring.

Major Interactions (Avoid): - NSAIDs: increase risk of renal toxicity. - Penicillins (e.g., ampicillin): raise methotrexate plasma levels. - Sulfonamides: reduce renal clearance, heightening toxicity.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect methotrexate elimination. - Warfarin: can enhance anticoagulant effect, requiring INR monitoring.